





20) **B**, Pd(dppf)Cl₂, Cs₂CO₃, Δ

GS-6207 (also known as lenacapavir) is a HIV capsid inhibitor and is currently in phase 2/3 clinical trials. It inhibits replication of HIV in cells at 105 pM and significantly reduces the viral load in patiens with multi-drug resistant HIV, while staying at antiviral levels in the plasma over 6 months. In contrast to previous agents that target enzymes in the HIV life cycle (do you know which ones?) GS-6207 actually accelerates capsid assembly, leading to malformed capsids, that